Table 3. Local injection site and systemic reactions.

		Number (%) of subjects a
		18–60 y	≥61 y	Total
		(n = 63)	(n = 63)	(n = 126)
Any		45 (71%)	31 (49%)	76 (60%)
Injection site reactions (Day 1 – Day 4 post vaccination)
Any		30 (48%)	22 (35%)	52 (41%)
Ecchymosis (mm)	Any	1 (2%)	4 (6%)	5 (4%)
	>50 mm	0	0	0
Erythema (mm)	Any	1 (2%)	0	1 (1%)
	>50 mm	0	0	0
Induration (mm)	Any	0	2 (3%)	2 (2%)
	>50 mm	0	0	0
Swelling (mm)	Any	1 (2%)	2 (3%)	3 (2%)
	>50 mm	0	0	0
Pain	Any	29 (46%)	17 (27%)	46 (37%)
	Severe	0	0	0
Systemic reactions (Day 1–Day 4 post vaccination)
Any		39 (62%)	20 (32%)	59 (47%)
Chills/ shivering	Any	1 (2%)	1 (2%)	2 (2%)
	Severe	0	0	0
Malaise	Any	5 (8%)	2 (3%)	7 (6%)
	Severe	0	0	0
Myalgia	Any	27 (43%)	12 (19%)	39 (31%)
	Severe	0	0	0
Arthralgia	Any	2 (3%)	0	2 (2%
	Severe	0	0	0
Headache	Any	13 (21%)	4 (6%)	17 (13%)
	Severe	0	0	0
Sweating	Any	10 (16%)	7 (11%)	17 (13%)
	Severe	0	0	0
Fatigue	Any	15 (24%)	7 (11%)	22 (17%)
	Severe	0	0	0
Fever		0	0	0
Other reactions
Temperature	<36 °C	3 (5%)	11 (17%)	14 (11%)
	≥40	0	0	0

^a Local injection site and systemic reactions were recorded for all subjects who provided post vaccination safety data (safety set)